JWH-363
Chemical compound
- CA: Schedule II
- UK: Class B
- 1-Naphthyl{1-pentyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone
- 914458-33-6
Y
- 44418338
- 23277916 Y
- DTXSID701337009
- Interactive image
- CCCCCN1C=C(C=C1C2=CC(=CC=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
InChI
- InChI=1S/C27H24F3NO/c1-2-3-6-15-31-18-21(17-25(31)20-11-7-12-22(16-20)27(28,29)30)26(32)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3Y
- Key:GETLFVZYXNFVJS-UHFFFAOYSA-NY
JWH-363 (1-Naphthyl{1-pentyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 245 ± 5nM) and CB2 (Ki = 71 ± 1nM) receptors, with a moderate (~3.45x) selectivity for the latter. JWH-363 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]
Legality
In the United States JWH-363 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-363.[2][3][4][5]
In Canada, JWH-363 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-363 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.
See also
- List of JWH cannabinoids
- Synthetic cannabinoid
References
- ^ Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR (October 2006). "1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors". Bioorganic & Medicinal Chemistry Letters. 16 (20): 5432–5. doi:10.1016/j.bmcl.2006.07.051. PMID 16889960.
- ^ 21 U.S.C. § 812: Schedules of controlled substances
- ^ "The 2020 Florida Statutes". www.leg.state.fl.us. Retrieved 20 August 2021.
- ^ "Arizona Revised Statutes Title 13. Criminal Code § 13-3401". www.azleg.gov. Retrieved 20 August 2021.
- ^ "California Code, Health and Safety Code - HSC § 11357.5". Findlaw.
- v
- t
- e
Cannabinoids
(comparison)
| Cannabibutols |
|
|---|---|
| Cannabichromenes | |
| Cannabicyclols |
|
| Cannabidiols | |
| Cannabielsoins |
|
| Cannabigerols | |
| Cannabiphorols |
|
| Cannabinols | |
| Cannabitriols |
|
| Cannabivarins |
|
| Delta-8-tetrahydrocannabinols |
|
| Delta-9-tetrahydrocannabinols | |
| Delta-10-Tetrahydrocannabinols | |
| Miscellaneous cannabinoids |
|
| Active metabolites |
- Arachidonoyl ethanolamide (AEA; anandamide)
- 2-Arachidonoylglycerol (2-AG)
- 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
- 2-Oleoylglycerol (2-OG)
- N-Arachidonoyl dopamine (NADA)
- N-Arachidonylglycine (NAGly)
- 2-Arachidonoyl lysophosphatidylinositol (2-ALPI)
- N-Arachidonoyl serotonin (AA-5-HT)
- Docosatetraenoylethanolamide (DEA)
- Lysophosphatidylinositol (LPI)
- Oleamide
- Oleoylethanolamide (OEA)
- Palmitoylethanolamide (PEA)
- RVD-Hpα
- Stearoylethanolamide (SEA)
- O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
cannabinoid
receptor
agonists /
neocannabinoids
| Classical cannabinoids (dibenzopyrans) |
|
|---|---|
| Non-classical cannabinoids |
|
| Adamantoylindoles |
|
| Benzimidazoles | |
| Benzoylindoles |
|
| Cyclohexylphenols | |
| Eicosanoids |
|
| Hydrocarbons | |
| Indazole carboxamides | |
| Indazole-3- carboxamides |
|
| Indole-3-carboxamides |
|
| Indole-3-carboxylates | |
| Naphthoylindazoles | |
| Naphthoylindoles |
|
| Naphthoylpyrroles | |
| Naphthylmethylindenes | |
| Naphthylmethylindoles | |
| Phenylacetylindoles | |
| Pyrazolecarboxamides |
|
| Pyrrolobenzoxazines | |
| Quinolinyl esters | |
| Tetramethylcyclo- propanoylindazoles | |
| Tetramethylcyclo- propanoylindoles | |
| Tetramethylcyclo- propylindoles | |
| Others |
|
enhancers
(inactivation inhibitors)
- 4-Nonylphenylboronic acid
- AM-404
- Arachidonoyl serotonin
- Arvanil
- BIA 10-2474
- Biochanin A
- CAY-10401
- CAY-10429
- Genistein
- Guineesine
- IDFP
- JNJ 1661010
- JNJ-42165279
- JZL184
- JZL195
- Kaempferol
- LY-2183240
- MK-4409
- O-1624
- O-2093
- Oleoylethanolamide (OEA)
- Olvanil
- Palmitoylethanolamide (PEA)
- PF-04457845
- PF-622
- PF-750
- PF-3845
- PHOP
- URB-447
- URB-597
- URB-602
- URB-754
- VDM-11
(antagonists/inverse
agonists/antibodies)
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- BML-190
- Brizantin (Бризантин)
- CAY-10508
- CB-25
- CB-52
- CB-86
- Dietressa (Диетресса)
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PipISB
- PSB-SB-487
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TM-38837
- VCHSR
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
